Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1954 5
1955 3
1956 1
1957 1
1958 5
1959 3
1964 1
1965 6
1966 19
1967 18
1968 19
1969 32
1970 22
1971 34
1972 22
1973 29
1974 35
1975 36
1976 32
1977 43
1978 43
1979 51
1980 46
1981 54
1982 78
1983 65
1984 75
1985 64
1986 81
1987 72
1988 70
1989 91
1990 171
1991 132
1992 126
1993 98
1994 104
1995 106
1996 119
1997 109
1998 112
1999 129
2000 132
2001 142
2002 154
2003 169
2004 165
2005 162
2006 208
2007 204
2008 199
2009 272
2010 266
2011 233
2012 284
2013 285
2014 327
2015 305
2016 325
2017 312
2018 387
2019 358
2020 363
2021 338
2022 290
2023 258
2024 116

Text availability

Article attribute

Article type

Publication date

Search Results

7,839 results

Results by year

Filters applied: . Clear all
Page 1
The Cytokines of Asthma.
Lambrecht BN, Hammad H, Fahy JV. Lambrecht BN, et al. Immunity. 2019 Apr 16;50(4):975-991. doi: 10.1016/j.immuni.2019.03.018. Immunity. 2019. PMID: 30995510 Free article. Review.
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis. ...
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway …
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
We assessed its efficacy and safety in patients with uncontrolled asthma. METHODS: We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or m …
We assessed its efficacy and safety in patients with uncontrolled asthma. METHODS: We randomly assigned 1902 patients 12 years of age …
Update on eosinophilic granulomatosis with polyangiitis.
Furuta S, Iwamoto T, Nakajima H. Furuta S, et al. Allergol Int. 2019 Oct;68(4):430-436. doi: 10.1016/j.alit.2019.06.004. Epub 2019 Jun 29. Allergol Int. 2019. PMID: 31266709 Free article. Review.
Eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome) is a rare form of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small to medium-size vessel vasculitis associat …
Eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome) is a rare form of anti-neutrophil cytoplasm antibody …
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, Spechler SJ, Attwood SE, Straumann A, Aceves SS, Alexander JA, Atkins D, Arva NC, Blanchard C, Bonis PA, Book WM, Capocelli KE, Chehade M, Cheng E, Collins MH, Davis CM, Dias JA, Di Lorenzo C, Dohil R, Dupont C, Falk GW, Ferreira CT, Fox A, Gonsalves NP, Gupta SK, Katzka DA, Kinoshita Y, Menard-Katcher C, Kodroff E, Metz DC, Miehlke S, Muir AB, Mukkada VA, Murch S, Nurko S, Ohtsuka Y, Orel R, Papadopoulou A, Peterson KA, Philpott H, Putnam PE, Richter JE, Rosen R, Rothenberg ME, Schoepfer A, Scott MM, Shah N, Sheikh J, Souza RF, Strobel MJ, Talley NJ, Vaezi MF, Vandenplas Y, Vieira MC, Walker MM, Wechsler JB, Wershil BK, Wen T, Yang GY, Hirano I, Bredenoord AJ. Dellon ES, et al. Gastroenterology. 2018 Oct;155(4):1022-1033.e10. doi: 10.1053/j.gastro.2018.07.009. Epub 2018 Sep 6. Gastroenterology. 2018. PMID: 30009819 Free PMC article. Review.
Pediatric and adult physicians and researchers from gastroenterology, allergy, and pathology subspecialties representing 14 countries used online communications, teleconferences, and a face-to-face meeting to review the literature and clinical experiences. RESULTS: Substan …
Pediatric and adult physicians and researchers from gastroenterology, allergy, and pathology subspecialties representing 14 countries used o …
Morphea and Eosinophilic Fasciitis: An Update.
Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Mertens JS, et al. Am J Clin Dermatol. 2017 Aug;18(4):491-512. doi: 10.1007/s40257-017-0269-x. Am J Clin Dermatol. 2017. PMID: 28303481 Free PMC article. Review.
Likewise, these processes are considered essential in systemic sclerosis (SSc) pathogenesis. In addition, similarities in clinical presentation between morphea and SSc have led to many theories about their relatedness. Importantly, morphea may be differentiated from SSc ba …
Likewise, these processes are considered essential in systemic sclerosis (SSc) pathogenesis. In addition, similarities in clinical pr …
Update on the classification and treatment of localized scleroderma.
Bielsa Marsol I. Bielsa Marsol I. Actas Dermosifiliogr. 2013 Oct;104(8):654-66. doi: 10.1016/j.adengl.2012.10.012. Epub 2013 Aug 13. Actas Dermosifiliogr. 2013. PMID: 23948159 Free article. Review.
It comprises a number of subtypes differentiated according to their clinical presentation and the structure of the skin and underlying tissues involved in the fibrotic process. ...
It comprises a number of subtypes differentiated according to their clinical presentation and the structure of the skin and underlyin …
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Rabe KF, et al. N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782224 Free article. Clinical Trial.
After a glucocorticoid dose-adjustment period before randomization, glucocorticoid doses were adjusted in a downward trend from week 4 to week 20 and then maintained at a stable dose for 4 weeks. ...Injection-site reactions were more common with dupilumab than with placebo …
After a glucocorticoid dose-adjustment period before randomization, glucocorticoid doses were adjusted in a downward trend from week …
Medical treatment of eosinophilic esophagitis.
Franciosi JP, Gordon M, Sinopoulou V, Dellon ES, Gupta SK, Reed CC, Gutiérrez-Junquera C, Venkatesh RD, Erwin EA, Egiz A, Elleithy A, Mougey EB. Franciosi JP, et al. Cochrane Database Syst Rev. 2023 Jul 20;7(7):CD004065. doi: 10.1002/14651858.CD004065.pub4. Cochrane Database Syst Rev. 2023. PMID: 37470293 Free PMC article. Review.
Current guidelines no longer require the failure of response to proton pump inhibitor medications to establish a diagnosis of EoE, but continue to suggest the exclusion of other etiologies of esophageal eosinophilia. The treatment goals for EoE are improvement in clinic …
Current guidelines no longer require the failure of response to proton pump inhibitor medications to establish a diagnosis of EoE, but conti …
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Pavord ID, et al. Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X. Lancet. 2012. PMID: 22901886 Clinical Trial.
METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. ...Patients, clinicians, and data analysts were masked to treatment assignment. Analyses were by intention to treat. This tria …
METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and De …
Tezepelumab in patients with allergic and eosinophilic asthma.
Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, Lommatzsch M, Martin N, Matucci A, Nasser SM, Pavord ID, Domingo C. Caminati M, et al. Allergy. 2024 May;79(5):1134-1145. doi: 10.1111/all.15986. Epub 2023 Dec 26. Allergy. 2024. PMID: 38146651 Review.
7,839 results